Monoconjugation of Human Amylin with Methylpolyethylen

DOI: 10.1371/journal.pone.0138803
PLoS ONE, 2015, 10, e0138803.

#	Paper	IF	Citations
18	Amyloidogenesis of the amylin analogue pramlintide. *Biophysical Chemistry*, **2016**, 219, 1-8	3.5	29
17	Regulation of the assembly and amyloid aggregation of murine amylin by zinc. *Biophysical Chemistry*, **2016**, 218, 58-70	3.5	26
16	Leptin influences the excitability of area postrema neurons. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2016**, 310, R440-8	3.2	14
15	Subclinical Diabetes. *Anais Da Academia Brasileira De Ciencias*, **2017**, 89, 591-614	1.4	13
14	Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. *British Journal of Pharmacology*, **2018**, 175, 3-17	8.6	181
13	PEGylated prodrugs of antidiabetic peptides amylin and GLP-1. *Journal of Controlled Release*, **2018**, 292, 58-66	11.7	6
12	Physico-chemical properties of co-formulated fast-acting insulin with pramlintide. *International Journal of Pharmaceutics*, **2018**, 547, 621-629	6.5	12
11	Physico-chemical stability of co-formulation of PEGylated human amylin with insulin. *Pharmaceutical Development and Technology*, **2019**, 24, 975-981	3.4	7
10	BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats. *Peptides*, **2019**, 114, 44-49	3.8	9
9	Heterotropic Modulation of Amylin Fibrillation by Small Molecules: Implications for Formulative Designs. *Protein Journal*, **2020**, 39, 10-20	3.9	2
8	GLP-1R agonists for the treatment of obesity: a patent review (2015-present). *Expert Opinion on Therapeutic Patents*, **2020**, 30, 781-794	6.8	4
7	A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs. *Nature Biomedical Engineering*, **2020**, 4, 507-517	19	28
6	Stable Monomeric Insulin Formulations Enabled by Supramolecular PEGylation of Insulin Analogues. *Advanced Therapeutics*, **2020**, 3, 1900094	4.9	14
5	Physico-chemical properties of co-formulation of insulin with pramlintide.		
4	Amyloidogenicity of peptides targeting diabetes and obesity. *Colloids and Surfaces B: Biointerfaces*, **2022**, 209, 112157	6	1
3	Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists.. *European Journal of Medicinal Chemistry*, **2022**, 236, 114330	6.8	1
2	Unambiguous characterization of PEGylation site on human amylin by two-dimensional nuclear magnetic resonance spectroscopy. *Peptide Science*, **2022**, 114,	3	

1	Studies on alpha-synuclein and islet amyloid polypeptide interaction. 10,	0